Beta

    fda approve camizestrant for advanced breast cancer

    Before Jul 1, 2026

    fda approve camizestrant for advanced breast cancer. Best Yes near 14¢ across 1 platform. Live cross-platform prices. Not financial advice.

    Best Yes: 14¢ · Best No: 88¢ · 1 platform

    • Kalshi: Yes 14¢ / No 88¢
    LIVE

    Before Jul 1, 2026

    Volume

    $1.8K

    $4 24h

    Platforms

    1

    Cross-platform pricing

    Resolution

    Resolves Jul 1, 2026

    ~15 days left

    Category

    Culture

    14¢CHANCE OF YES14%86%
    Yes
    14¢
    Kalshi
    No
    88¢
    Kalshi

    Opens on best-price platform

    Compare & Trade

    1 platform
    KalshiKalshi
    Best Yes
    Best No
    Yes
    14¢
    No
    88¢
    Vol
    $1.8K
    $4 24h
    Trade on Kalshi

    Price History

    Loading…

    About This Market

    If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jul 1, 2026, then the market resolves to Yes.

    Fee Impact at These Prices

    KalshiKalshiat 14¢: exit costs ~0.84¢/contract
    Full calculator

    Market Details

    ResolutionResolves Jul 1, 2026
    Time Left15 days
    Status● Active
    CategoryCulture

    Sign in to join the discussion

    Sign In